Bowman v. SP Pharmaceuticals

CourtCourt of Appeals for the Tenth Circuit
DecidedDecember 5, 2000
Docket99-2317
StatusUnpublished

This text of Bowman v. SP Pharmaceuticals (Bowman v. SP Pharmaceuticals) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bowman v. SP Pharmaceuticals, (10th Cir. 2000).

Opinion

F I L E D United States Court of Appeals Tenth Circuit UNITED STATES COURT OF APPEALS DEC 5 2000 TENTH CIRCUIT PATRICK FISHER Clerk

MATTHEW BOWMAN,

Plaintiff - Appellant, No. 99-2317 v. D. New Mexico SP PHARMACEUTICALS, L.L.C., (D.C. No. CIV-98-415-LH/RLP) a New Mexico company; SP ASSOCIATES, INC., a New Mexico corporation; H. JOSEPH LARSEN; DONALD E. HAGMAN; and FERNANDO A. CORREA da COSTA,

Defendants - Appellees.

ORDER AND JUDGMENT *

Before TACHA , ANDERSON , and BALDOCK , Circuit Judges.

Appellant Matthew F. Bowman brought this diversity action against SP

Pharmaceuticals, L.L.C. (“SPLLC”), SP Associates, Inc. (“SPINC”), H. Joseph

Larsen, Donald E. Hagman, and Fernando A. Correa da Costa after the individual

defendants expelled him from a management buyout partnership (the “MBO

* This order and judgment is not binding precedent, except under the doctrines of law of the case, res judicata, and collateral estoppel. The court generally disfavors the citation of orders and judgments; nevertheless, an order and judgment may be cited under the terms and conditions of 10th Cir. R. 36.3. Partnership”). Appellant’s complaint asserted breach of fiduciary duty, fraud,

prima facie tort, derivative usurpation of corporate opportunity and constructive

trust claims. The district court granted Defendants’ motion for summary

judgment on all claims, holding that (1) because Appellant and the individual

defendants agreed to abandon SPINC, Appellant may not assert claims on its

behalf, and (2) since any opportunity enjoyed by Appellant was contingent on

obtaining financing, the bank’s independent decision not to finance a transaction

involving Appellant requires that summary judgment be granted as to the breach

of fiduciary duty and constructive trust claims.

On appeal, Appellant contends that the district court erred in granting

summary judgment in favor of Defendants on the breach of fiduciary duty, fraud,

derivative and constructive trust claims because: (1) regardless of the bank’s

position, genuine issues of material fact exist as to whether the individual

defendants breached their fiduciary duties to Appellant; (2) triable issues of fact

exist regarding the individual defendants’ motives and state of mind when they

represented to Appellant that he was a partner; (3) the court failed to take into

consideration that the Letter of Intent (“LOI”) between SPINC and Pharmacia &

Upjohn, Inc. (“P&U”) was never formally transferred to SPLLC; and (4) a

constructive trust may arise because there are triable issues of fact as to whether

-2- the individual defendants breached their fiduciary duties to Appellant. We

exercise jurisdiction pursuant to 18 U.S.C. § 1291, and affirm.

I. BACKGROUND

In early 1996, the individual defendants formed the MBO Partnership to

pursue the acquisition of a sterile injectable pharmaceuticals facility (the

“Facility”) from P&U. Appellant agreed to become the fourth partner in the MBO

Partnership in April of 1996. He was to be the vice president of sales and

marketing of the acquiring entity and was to hold an equity share in that entity

equal to that of each individual defendant. The partners agreed that Appellant

would relocate from Ohio to New Mexico after the transaction closed in order to

devote his full attention to the new venture.

On May 21, 1996, the four partners incorporated SPINC. Appellant and the

individual defendants were SPINC’s sole directors, officers and shareholders. 1 In

December of 1996, SPINC entered into the LOI with P&U. The LOI referred to

Appellant as an officer and director of SPINC and stated that the LOI

memorialized recent negotiations for the purchase of the Facility by “SP

Associates, or its assignee, which will be controlled by the current owners of SP

Associates, Inc.” Appellant’s App. at 280. The LOI provided that P&U would

1 The SPINC shares apparently were never issued.

-3- sell the Facility to SPINC for $20,550,000 and that P&U would not, until the

termination of the LOI, negotiate a sale of the Facility with any other buyer. The

LOI was contingent on SPINC obtaining adequate financing.

In January of 1997, the four partners met to discuss the transaction. The

results of those discussions are found in a letter from da Costa to Appellant,

Larsen and Hagman dated January 28, 1997 (the “da Costa Letter”). The da Costa

Letter states that the partners agreed to use NationsBank (“NB”) to finance the

transaction. Id. at 290. In addition, the da Costa Letter states that the partners,

who were SPINC’s sole directors, officers and shareholders, unanimously agreed

to abandon that entity and use a limited liability company (“LLC”) as the

acquisition vehicle. Id. at 291.

On January 31, 1997, NB sent a letter to Larsen and Hagman formally

proposing to finance the acquisition of the Facility. The proposed equity and

ownership split was 40% for NB and 60% for the partners. NB’s proposal also

recognized that an LLC would be used to acquire the Facility. On March 28,

1997, Larsen, on behalf of the MBO Partnership, formed SPLLC. Larsen and

Hagman were the initial members, and Larsen the manager, of SPLLC. The

Organizing Operating Agreement authorized Larsen to execute a Membership

Subscription Agreement between SPLLC and NB and a new operating agreement

between SPLLC, NB, da Costa, Larsen, Hagman and others.

-4- After receiving data indicating a decrease in the Facility’s projected

financial performance, NB revised the equity and ownership split in its financing

proposal such that its share was increased to 70% and the partners’ share was

decreased to 30%. However, the partners would retain 60% voting control. The

partners attempted in vain to obtain more equity from NB.

Once it became clear that NB would not increase the partners’ equity

position, Appellant apparently became unsettled about the transaction. It was

Appellant’s opinion that he had more at stake in the venture than the other three

partners because he was the only partner relocating his family and incurring

significant additional debt. Id. at 334. In an attempt to make up for his reduction

in equity, Appellant made various written proposals to the other partners on May

27, 1997. Appellant suggested that SPLLC pay him performance bonuses

potentially worth millions of dollars, increase his bonus from $35,000 to $45,000

payable immediately, reimburse him for his daughter’s private school tuition, pay

him a $700 a month car allowance, reimburse him for relocation costs, guarantee

a minimum selling price for his home in Ohio and execute an employment

contract guaranteeing his salary and bonus for at least two years. Id. at 513-18.

The individual defendants reacted negatively to Appellant’s proposals.

Aside from being unwilling to give Appellant a package worth millions of dollars

more than their own, they feared that Appellant’s attempt to renegotiate his deal

-5- would jeopardize the MBO Partnership’s ability to finance the acquisition. On

May 28, 1997, da Costa wrote to Larsen and Hagman stating that they should give

Appellant written notice that he was expelled from the MBO Partnership. Larsen

drafted a memo dated May 29, 1997, informing Appellant that he was no longer a

partner in the MBO Partnership.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Citizens Bank of Clovis v. Williams
630 P.2d 1228 (New Mexico Supreme Court, 1981)
GCM, Inc. v. Kentucky Central Life Insurance
947 P.2d 143 (New Mexico Supreme Court, 1997)
Holman v. Coie
522 P.2d 515 (Court of Appeals of Washington, 1974)
Bassett v. Bassett
798 P.2d 160 (New Mexico Supreme Court, 1990)
Levy v. Disharoon
749 P.2d 84 (New Mexico Supreme Court, 1988)
Petty v. Bank of New Mexico Holding Co.
787 P.2d 443 (New Mexico Supreme Court, 1990)
Cargill v. Sherrod
631 P.2d 726 (New Mexico Supreme Court, 1981)
St. Joseph's Regional Health Center v. Munos
934 S.W.2d 192 (Supreme Court of Arkansas, 1996)
Bohatch v. Butler & Binion
977 S.W.2d 543 (Texas Supreme Court, 1998)
Leigh v. Crescent Square, Ltd.
608 N.E.2d 1166 (Ohio Court of Appeals, 1992)
Waite ex rel. Bretton Woods Acquisition Co. v. Sylvester
560 A.2d 619 (Supreme Court of New Hampshire, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
Bowman v. SP Pharmaceuticals, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bowman-v-sp-pharmaceuticals-ca10-2000.